Ibopamine in the treatment of mild chronic heart failure in elderly patients: A double-blind, placebo-controlled study

Benzi Azzolini, C. Pizzomi, E. Guffanti, M. Ronzitti, L. Tantalo

Research output: Contribution to journalArticle


This double-blind, randomized, multicentcr clinical study assessed the efficacy and safety of ibopamine 100 mg t.i.d. as monotherapy vs. placebo in 52 patients with mild chronic heart failure aged over 60 years during a 12-weektreatment period. Ibopamine produced a statistically significant increase in exercise tolerance and reduction in fatigue during effort compared to placebo. A trend towards decreased requirement of concomitant diuretic therapy was noted in the ibopaminc-treated group. Ibopamine was well tolerated throughout the study. This study indicated that ibopamine is an effective and safe agent as monotherapy in the treatment of mild chronic heart failure in elderly patients.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
Publication statusPublished - 1990



  • Chronic
  • Elderly
  • heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this